It will be at least another year before a vaccine against the new coronavirus will be ready for approval and available in sufficient quantities, the EU medicines agency said Tuesday.
As the number of declared coronavirus cases worldwide passed 800,000 on Tuesday, according to an AFP tally, the race is on to develop a vaccine against COVID-19 which emerged from China late last year.
The European Medicines Agency said in a statement it "estimates that it might take at least one year before a vaccine against COVID-19 is ready for approval and available in sufficient quantities to enable widespread use".
This was based on current available information and past experience with vaccine development timeframes, the Amsterdam-based agency said.
It added that two vaccines have already entered a first phase of a clinical trials that was carried out on healthy volunteers.
But in general "timelines for the development of medicinal products are difficult to predict", the EMA said.
So far, no medicine has yet shown to be a treatment for the coronavirus, that has so far claimed some 40,000 lives.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
